Compare Moody's Corporation (MCO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs GeneDx Holdings Corp — how do they compare? Moody's Corporation trades at $477.07 (market cap $82.52B), while GeneDx Holdings Corp trades at $82.28 (market cap $2.44B). The key difference: Moody's Corporation is far larger — about 33.8× GeneDx Holdings Corp's market cap, and Moody's Corporation pays a 0.86% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MCO | WGS | |
|---|---|---|
Market Cap | $82.52B | $2.44B |
Sector | Financials | Technology |
52-Week High | $539.61 | $167.51 |
52-Week Low | $412.23 | $34.51 |
Enterprise Value | $88.54B | $2.48B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $477.00, down 0.24% on the day, with strong fundamentals including 80.15% ROE and 34.25% net margin. The stock shows bearish technical signals but maintains robust earnings momentum with three consecutive quarterly beats. Revenue growth accelerated to $7.72 billion in 2025, while analyst consensus remains bullish with a $561.88 price target representing 18% upside potential.
MCO presents a compelling growth story with premium valuation metrics (P/E 30.23) justified by consistent earnings outperformance and dominant market position. Key risks include sensitivity to debt issuance cycles and elevated valuation multiples. The combination of strong profitability, analyst support, and dividend payments supports a positive long-term outlook despite near-term technical weakness.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
